|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-12-12
|
|
pubmed:abstractText |
Combined hyperlipidemia (CHL) is a very frequent dyslipidemia, being lipid-lowering drugs often necessary in its management. Some genetic loci have been associated with CHL, and modulation of lipid-lowering treatment by genetic polymorphisms has been reported. We have investigated whether common polymorphisms in the hepatic lipase gene (LIPC) influence the baseline lipid concentration and the response to atorvastatin or bezafibrate in patients with CHL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bezafibrate,
http://linkedlifedata.com/resource/pubmed/chemical/Cytosine,
http://linkedlifedata.com/resource/pubmed/chemical/Heptanoic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Lipase,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/Thymine,
http://linkedlifedata.com/resource/pubmed/chemical/atorvastatin,
http://linkedlifedata.com/resource/pubmed/chemical/hepatic lipase, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
pubmed-author:ATOMIX Study Group,
pubmed-author:ArísteguiRosaR,
pubmed-author:ArtiedaMartaM,
pubmed-author:CenarroAnaA,
pubmed-author:CiveiraFernandoF,
pubmed-author:DíazCristinaC,
pubmed-author:GañánAlbertoA,
pubmed-author:GonzalvoCarmenC,
pubmed-author:Meriño-IbarraErardoE,
pubmed-author:PocovíMiguelM,
pubmed-author:SolJosep MaríaJM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
150
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1154-62
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16338252-Adult,
pubmed-meshheading:16338252-Aged,
pubmed-meshheading:16338252-Bezafibrate,
pubmed-meshheading:16338252-Cytosine,
pubmed-meshheading:16338252-Female,
pubmed-meshheading:16338252-Genetic Variation,
pubmed-meshheading:16338252-Genotype,
pubmed-meshheading:16338252-Heptanoic Acids,
pubmed-meshheading:16338252-Humans,
pubmed-meshheading:16338252-Hyperlipidemias,
pubmed-meshheading:16338252-Hypolipidemic Agents,
pubmed-meshheading:16338252-Lipase,
pubmed-meshheading:16338252-Lipids,
pubmed-meshheading:16338252-Lipoproteins,
pubmed-meshheading:16338252-Male,
pubmed-meshheading:16338252-Middle Aged,
pubmed-meshheading:16338252-Polymerase Chain Reaction,
pubmed-meshheading:16338252-Polymorphism, Single Nucleotide,
pubmed-meshheading:16338252-Pyrroles,
pubmed-meshheading:16338252-Reference Values,
pubmed-meshheading:16338252-Thymine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
|
|
pubmed:affiliation |
Laboratorio de Investigación Molecular, Hospital Universitario Miguel Servet, Zaragoza, Spain.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
